NCT03838029View on ClinicalTrials.gov

Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Pancreatic Neoplasms
Interventions
DRUG

Propranolol and etodolac

A perioperative combined drug regimen

OTHER

Placebo

Placebo

Trial Locations (3)

45858

RECRUITING

Sheba Medical Center, Tel Litwinsky

70300

RECRUITING

Asaf Harofeh Medical Center, Ẕerifin

6423906

NOT_YET_RECRUITING

Sourasky Medical Center, Tel Aviv

All Listed Sponsors
collaborator

Sheba Medical Center

OTHER_GOV

lead

Assaf-Harofeh Medical Center

OTHER_GOV

NCT03838029 - Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery | Biotech Hunter | Biotech Hunter